Asparaginase

The U.S. food industry discovered an enzyme called asparaginase that can chew up asparagine in food products, so less acrylamide is formed.

Health Canada's safety assessment of the enzyme, which is called asparaginase, didn't turn up any health or safety concerns. ❋ Unknown (2009)

When a 12-year-old boy from Illinois with ALL arrived at St. Jude in 2001, Pui administered everything but the kitchen sink: the drugs prednisone, vincristine, daunorubicin, and asparaginase, followed by cyclophosphamide, cytarabine, and mercaptopurine. ❋ Unknown (2010)

Put simply, the kids are blasted with the highest doses of the most chemotherapy drugs they can stand — steroids and vinca alkaloids, asparaginase and anthracyclines and more. ❋ Unknown (2010)

This growth is primarily attributed to the expected launch of Phase III pipeline candidates Marqibo (vincristine sulfate liposomes injection), GRASPA (asparaginase loaded into erythrocytes), recombinant asparaginase (asparaginase) and Depocyt (liposomal cytarabine) during the forecast period.

Once susceptible batches are uncovered, the potato processing industry could ditch the guilty potatoes. asparaginase. ❋ Ariel Schwartz (2010)

Graspa is an experimental therapy that consists of red blood cell-encapsulated L-asparaginase, an enyzme used to treat leukemia by damaging cancer cells. ❋ Unknown (2010)

L-asparaginase is a critical and irreplaceable component of combination chemotherapy for ALL and has been used in the clinic for over 30 years. ❋ Unknown (2010)

By encapsulating the enzyme inside red blood cells, the company is seeking to make Graspa safer and have a broader range of clinical uses as compared to existing forms of L-asparaginase. ❋ Unknown (2010)

GRASPA® is a new enzyme formulation of L-asparaginase with a safer and broader range of clinical use's compared to existing forms due to the enzymes entrapment and protection inside the homologous red blood cell. ❋ Unknown (2010)

L-asparaginase (randomized) allowed to compensate for this disadvantage; in high-risk patients (HR, 15 %), substitution of intensive polychemotherapy blocks for conventional BFM backbone failed to improve results. ❋ V Conter (2010)

"We're very interested in studying GRASPA® because of its reported reduction of L-asparaginase side effects." ❋ Editors (2010)